Enlivex Therapeutics Files September 2024 6-K Report
Ticker: ENLV · Form: 6-K · Filed: Sep 11, 2024 · CIK: 1596812
Sentiment: neutral
Topics: foreign-private-issuer, sec-filing, reporting
Related Tickers: ENLV
TL;DR
Enlivex Therapeutics (ENLV) filed its monthly 6-K report on 9/11, standard foreign issuer update.
AI Summary
Enlivex Therapeutics Ltd. filed a Form 6-K on September 11, 2024, reporting on its activities for the month of September 2024. The filing is a report of a foreign private issuer and indicates that the company files annual reports under Form 20-F. The company's principal executive offices are located at 14 Einstein Street, Nes Ziona, Israel.
Why It Matters
This filing provides an update on Enlivex Therapeutics' ongoing reporting as a foreign private issuer, which is standard for companies listed on US exchanges but based internationally.
Risk Assessment
Risk Level: low — This filing is a routine report of a foreign private issuer and does not contain new financial or operational information that would typically increase risk.
Key Players & Entities
- Enlivex Therapeutics Ltd. (company) — Registrant
- September 11, 2024 (date) — Filing Date
- Form 6-K (document) — Filing Type
- Form 20-F (document) — Annual Report Form
- 14 Einstein Street, Nes Ziona, Israel (location) — Principal Executive Offices
FAQ
What is the purpose of a Form 6-K filing?
A Form 6-K is a report of foreign private issuers which provides information that the registrant makes or is required to make public pursuant to the laws of its home country, or is required to file with or submit to any stock exchange on which it has securities listed, or is distributed or is required to distribute to its security holders.
What is the filing date of this specific 6-K report?
The filing date for this 6-K report is September 11, 2024.
What type of annual report does Enlivex Therapeutics file?
Enlivex Therapeutics files its annual reports under cover of Form 20-F.
Where are Enlivex Therapeutics' principal executive offices located?
Enlivex Therapeutics' principal executive offices are located at 14 Einstein Street, Nes Ziona, Israel.
Is Enlivex Therapeutics a US-based company?
No, Enlivex Therapeutics Ltd. is identified as a foreign private issuer, with its principal executive offices in Israel.
Filing Stats: 279 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-09-11 08:30:22
Filing Documents
- ea0214057-6k_enlivex.htm (6-K) — 29KB
- ea021405701ex99-1_enlivex.htm (EX-99.1) — 269KB
- ea021405701ex99-2_enlivex.htm (EX-99.2) — 142KB
- tcheck_001.jpg (GRAPHIC) — 2KB
- 0001213900-24-077521.txt ( ) — 444KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.   Enlivex Therapeutics Ltd.     (Registrant)     By:   /s/ Oren Hershkovitz     Name:   Oren Hershkovitz     Title:   Chief Executive Officer Date: September 11, 2024 2